{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    9,
    11,
    12,
    13,
    14,
    22,
    24,
    25,
    26,
    28,
    30
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "181-06",
        "affectedSection": "Section 5.2.1.2.1 - Immune-Related Events and Dose Modification",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated dose modification and toxicity management guidelines for immune-related adverse events (irAEs) and associated tables."
      },
      {
        "id": "impact_2",
        "amendmentId": "181-06",
        "affectedSection": "Section 5.5.2 - Prohibited Concomitant Medication",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Clarified the status of COVID-19 vaccines as allowed concomitant medication."
      },
      {
        "id": "impact_3",
        "amendmentId": "181-06",
        "affectedSection": "Section 5.11 - Clinical Criteria for Early Trial Termination",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated criteria to allow for earlier study termination flexibility."
      },
      {
        "id": "impact_4",
        "amendmentId": "181-06",
        "affectedSection": "Section 5.10 - Beginning and End of the Trial",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added provisions for subject enrollment into a pembrolizumab extension study."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "181-06",
        "reasonText": "Requested by the U.S. Food and Drug Administration (FDA) to harmonize safety information across all FDA-approved PD-1/L1 antibody prescribing information.",
        "category": "Regulatory",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "181-06",
        "reasonText": "To clarify the concomitant use of COVID-19 vaccines.",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "181-06",
        "reasonText": "To add flexibility to allow the study to terminate before the planned completion date.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "181-06",
        "reasonText": "To align text with legal requirements to obtain informed consent documentation.",
        "category": "Regulatory",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "181-06",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.2.1.2.1",
        "beforeText": "Not specified",
        "afterText": "Updated dose modification and toxicity management guidelines for irAEs and table.",
        "summary": "Harmonized irAE management tables with FDA-approved prescribing information for PD-1/L1 antibodies."
      },
      {
        "id": "change_2",
        "amendmentId": "181-06",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "5.5.2",
        "beforeText": "Not specified",
        "afterText": "Any COVID-19 vaccine that is licensed in a given country is allowed in the study.",
        "summary": "Added explicit allowance for licensed COVID-19 vaccines."
      },
      {
        "id": "change_3",
        "amendmentId": "181-06",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "5.10",
        "beforeText": "Not specified",
        "afterText": "Upon study completion, subjects may be enrolled in a pembrolizumab extension study, if available.",
        "summary": "Added language regarding transition to extension studies."
      },
      {
        "id": "change_4",
        "amendmentId": "181-06",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "7.1.1.8",
        "beforeText": "Not specified",
        "afterText": "If subjects are rerandomized, each subject will retain his/her original treatment/randomization number.",
        "summary": "Clarified subject ID retention for extension study enrollment."
      },
      {
        "id": "change_5",
        "amendmentId": "181-06",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Overall",
        "beforeText": "Not specified",
        "afterText": "Minor editorial changes.",
        "summary": "General editorial updates for clarity throughout the document."
      }
    ],
    "summary": {
      "impactCount": 4,
      "reasonCount": 4,
      "changeCount": 5
    }
  }
}